Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apex BiotechnologyTPE:1733 +1.16%80 Days Inventory is 161.99 as of Dec. 2025, which is 13% above its 10-year median of 143.30. GuruFocus rates TPE:1733 with a GF Score™ of 80/100 and a GF Value™ of NT$30.06 (Fairly Valued). The stock has 2 warning signs investors should review. Among 638 Biotechnology companies, Apex Biotechnology ranks better than 58.31% on this metric.
The historical rank and industry rank for Apex Biotechnology's Days Inventory or its related term are showing as below:
TPE:1733'
s Days Inventory Range Over the Past 10 Years
Min: 119.72 Med: 143.3 Max: 236.92
Current: 150.39
During the past 13 years, Apex Biotechnology's highest Days Inventory was 236.92. The lowest was 119.72. And the median was 143.30.
TPE:1733's Days Inventory is ranked better than 58.31% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs TPE:1733: 150.39
Apex Biotechnology's Days Inventory
declined
from Dec. 2024 (194.46) to Dec. 2025 (161.99).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Apex Biotechnology's Inventory Turnover for the
three
months ended in Dec. 2025 was 0.56.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Apex Biotechnology's Inventory-to-Revenue for the
three
months ended in Dec. 2025 was 1.24.
Apex Biotechnology (TPE:1733) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Apex Biotechnology's Inventory Turnover for the
three
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Apex Biotechnology's Inventory to Revenue for the
three
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Apex Biotechnology Days Inventory Related Terms
Apex Biotechnology Days Inventory Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Apex Biotechnology's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Days Inventory distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Biotechnology (TPE:1733) has a Days Inventory of 161.99 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Apex Biotechnology and its competitors. This is 13% above median its historical median of 143.30. Over the past decade, Apex Biotechnology's Days Inventory has ranged from 119.72 to 236.92. According to the industry distribution chart, Apex Biotechnology ranks #266 out of 638 companies in the Biotechnology industry, placing it in the top 41.7%.
Is Apex Biotechnology's Days Inventory too high?
Apex Biotechnology's current Days Inventory of 161.99 is 13% above median its 10-year median of 143.30. Over the past 10 years, this metric has ranged from a low of 119.72 to a high of 236.92. The Biotechnology industry median Days Inventory is 183.20. Apex Biotechnology's value of 161.99 is 11.6% below this industry median. Based on the distribution chart, Apex Biotechnology ranks #266 out of 638 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Apex Biotechnology has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #266 out of 638 companies for Days Inventory. This puts Apex Biotechnology in the upper half of its industry. The industry median Days Inventory is 183.20. Apex Biotechnology's value of 161.99 is 11.6% below this benchmark. Historically, Apex Biotechnology's own Days Inventory has ranged from 119.72 to 236.92 over the past decade. While the company's 10-year median is 143.30 vs. the industry median of 183.20, Apex Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Biotechnology's current Days Inventory of 161.99 is 11.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Apex Biotechnology and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Biotechnology's current Days Inventory is 161.99, which is 13% above median its own 10-year median of 143.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.06, compared to a current price of NT$30.65 — trading 2% above its estimated fair value. The current Days Inventory is 161.99, which is 13% above median its 10-year median of 143.30 and 11.6% below the Biotechnology industry median of 183.20. Apex Biotechnology's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Days Inventory is 161.99 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be overvalued.
The current stock price of NT$30.65 is trading 2% above its estimated GF Value™ of NT$30.06.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
Days Inventory: 161.99 (13% above median its 10-year median of 143.30)
GF Value™: NT$30.06 vs. price of NT$30.65 (2% above fair value)
Industry Position: 11.6% below the Biotechnology median (#266 of 638)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
80GF Score
Get the complete analysis for TPE:1733
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
